When less is more in the intensive care unit; lessons learned

Bosnian Journal of Basic Medical Sciences

Volumn 9, Issue SUPPL., 2009, Pages

  Festic, Emir ^a   Gajic, Ognjen ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

Evidence based; First do no harm; Intensive care

Indexed keywords

CORTICOSTEROID; DROTRECOGIN; PROTEIN C; RECOMBINANT PROTEIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BLOOD TRANSFUSION; EVIDENCE BASED MEDICINE; FLUID THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; SEPTIC SHOCK;

ADRENAL CORTEX HORMONES; BLOOD GLUCOSE; BLOOD TRANSFUSION; EVIDENCE-BASED MEDICINE; FLUID THERAPY; HUMANS; INTENSIVE CARE UNITS; PROTEIN C; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, ADULT; SHOCK, SEPTIC;

EID: 73949136937     PISSN: 15128601     EISSN: 18404812     Source Type: Journal    
DOI: 10.17305/bjbms.2009.2763     Document Type: Article

References (30)

1. Bernard G.R., Vincent J.L., Laterre P.F. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 2001; 344:699-709.
2. Van den Berghe G., Wouters P., Weekers F. et al. Intensive insulin therapy in the critically ill patients. N. Eng. J. Med. 2001;345:1359-1367.
3. Festic E., Rickman O. ABCs of evidence-based critical care. Unpublished.
4. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. 2000; 342:1301-1308.
5. Meade M.O., Cook D.J., Guyatt G.H., et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high posi tive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome. JAMA. 2008;299(6):637-645.
6. Mercat A., Richard J-C. M., Vielle B. et al. Positive End-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial JAMA. 2008;299(6):646-655.
7. Hebert P.C., Wells G., Blajchman M.A., Marshall J., Martin C., Pa-gliarello G., Tweeddale M., Schweitzer I., Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N. Engl. J. Med. 1999;340(6):409-417.
8. Gajic O., Moore S.B. Transfusion-related acute lung injury. Mayo Clin. Proc. 2005;80(6):766-770.
9. Eder A.F., Chambers L.A. Noninfectious complications of blood transfusion. Arch. Pathol. Lab. Med. 2007; 131(5):708-18.
10. Annane D., Sebille V., Charpentier C., Bollaert P.E., Francois B. et a. Effect of treatment with low doses of hydrocortisone and hydrocortisone on mortality in patients with septic shock. JAMA 2002;288(7):862-871.
11. Sprung C.L., Annane D., Keh D., et al. hydrocortisone therapy for patients with septic shock. NEJM 2008:358:111.
12. Abraham E. et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New. Eng J. Med. 2005 353:1332-1341.
13. Wheeler A. et al. A retrospective observational study of drotreco-gin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. Crit. Care Med. 2008; 36(1):14-23.
14. Gentry C.A. et al. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions Crit. Care Med. 2009; 7(1):19-25.
15. Eisenberg P. Re: Discontinuation of study F1K-MC-EVBP, investigation of the efficacy and safety of drotrecogin alfa (activated) in pediatric severe sepsis. http://www.fda.gov/medwatch/safe-ty/2005/Xigris_dearhcp_4-21-05.htm
16. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med 2001; 345:1368-77.
17. Marik P.E., Goal-directed therapy for severe sepsis. NEJM 2002; 346:1025-1026.
18. NHLBI ARDS Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. NEJM 2006 354:2564-2575.
19. Finfer S., Bellomo R., Boyce. et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N. Engl. J. Med. 2004;350:2247-2256.
20. Myburgh J., Cooper D.J. et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N. Engl. J. Med. 2007;357:874-884.
21. Schortgen F., Lacherade J.C., Bruneel F. et al. Effects of hydroxy-ethylstarch and gelatin on renal function in severe sepsis: a multicentre randomized study. Lancet. 2001;357:911-916.
22. Brunkhorst F.M., Engel C., Bloos F. et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N. Engl. J Med. 2008;358:125-139.
23. Van den Berghe G. et al. Intensive insulin therapy in the medical ICU. N. Engl. J. Med. 2006;354:449-461.
24. Vriesendorp T.M. et al. Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Crit. Care Med. 2006; 34(11): 2714-2718
25. Krinsley J.S. Severe hypoglycemia in critically ill patients: Risk factors and outcomes. Crit. Care Med. 2007 35(10):2262-2267.
26. Soylemez Wiener R. et al. Benefits and risks of tight glucose control in critically ill adults: A meta-analysis. JAMA 2008;300(8):933-944.
27. Arabi Y.M., Dabbagh O.C., Tamim H.M., Al-Shimemeri A.A. et al. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit. Care Med. 2008;36:3190-3197.
28. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. NEJM 2009; 360:1283-1297.
29. Egi M. et al. Variability of blood glucose concentration and shortterm mortality un critically ill patients. Anesthesiology 2006; 105:244-252.
30. Ali N.A., O'Brien J.M. Jr., Dungan K., Phillips G., Marsh C.B., Lemeshow S., Connors A.F. Jr., Preiser J.C. Glucose variability and mortality in patients with sepsis. Crit. Care Med. 2008; 36:23162321.